Characterization of an orally available respiratory syncytial virus L protein polymerase inhibitor DZ7487.

ABSTRACT:

Objectives

Respiratory Syncytial Virus (RSV) is a leading cause of death and hospitalization among infants and young children. People with an immunocompromised status are also at risk for severe RSV infection. There is no specific treatment for RSV infection available. Ribavirin, an antiviral drug approved for severe lung infection by RSV, has shown limited clinical efficacies with severe side effects. Additionally, given the genetic variability of RSV genomes and seasonal change of different strains, a broad-spectrum antiviral drug is highly desirable. The RNA-dependent RNA polymerase (RdRp) domain is relatively conserved and indispensable for the replication of the virus genome and therefore serves as a potential therapeutic target. Previous attempts to identify an RdRp inhibitor

SUBMITTER: Guo Q 

PROVIDER: S-EPMC10086872 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature